Kevin Kunzmann

A study has found an alternative motor treatment from levodopa.

Researchers were able to pull 25,000 hours of monitoring data.

"We have some major changes in the way we treat Parkinson's."

The intravenous replacement therapy controls and prevents bleeding.

Fremanezumab reduced chronic migraine headache day rates.

John Dirk Nieland, PhD, associate professor in the Department of Health Science and Technology at Aalborg University in Denmark, discusses his research team's connection between MS and lipid metabolism, the importance of condition-inflicted models, and the encompassing nature of treating MS.

The ocular itching treatment is an ocular formulation of cetirizine.

The fixed-dose treatment from Gilead will be submitted for regulation.

Clyde Markowitz, MD, discusses how ocrelizumab, the most recent FDA-approved multiple sclerosis (MS) treatment, doesn't need to have "blockbuster" results to progress the state of MS treatment.

"We shouldn't reject these hypotheses, we should seek more data on them.

He and a Danish team believe they've found the cause of multiple sclerosis.

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.

The multi-dosage longterm studies of Cladribine Tablets were shared at CMSC.

The study was a continuation of a 2-year alemtuzumab study versus interferon.

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.

The 2nd of Celgene's phase III trials with the treatment proved promising.

A study of ACL-damaged rats shows molecular development of arthritis.

A deep brain stimulation treatment aids dyskinesia effects, study says.

Researchers studied administrative claims data from over a year.

The dual endothelin receptor antagonist caused early fluid retention.

The treatment reduced abnormal movements in patients, according to a study.

Warmer temperatures are affecting more pregnant women, study says.

Researcher calls it "some of the most exciting research in my career."